AIM
SUPN icon

Acrospire Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Acrospire Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,671
Closed -$72K – 1253
2017
Q2 		$72K Sell
1,671
-2,501
-60% -$89K 0.07% 505
2017
Q1 		$131K Sell
4,172
-4,998
-55% -$134K 0.11% 171
2016
Q4 		$232K Buy
9,170
+3,918
+75% +$87.5K 0.1% 264
2016
Q3 		$130K Sell
5,252
-3,000
-36% -$67.9K 0.09% 355
2016
Q2 		$168K Buy
8,252
+2,052
+33% +$36.4K 0.12% 149
2016
Q1 		$95K Buy
+6,200
New +$80.9K 0.07% 354

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Acrospire Investment Management's SUPN Position: Q3 2017 in Review

Acrospire Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 1,671 shares — an estimated $72K sold.

Acrospire Investment Management first reported a position in SUPN in Q1 2016 and held it in 6 quarters. The position peaked at $232K in Q4 2016. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

  • Acrospire Investment Management reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,671 Supernus Pharmaceuticals shares in Q3 2017, an estimated $72K.
  • Acrospire Investment Management first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Supernus Pharmaceuticals position peaked at $232K in Q4 2016.
  • 275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.